KR101508617B1 - 활성화된 폴리옥사졸린 및 이를 포함하는 조성물 - Google Patents

활성화된 폴리옥사졸린 및 이를 포함하는 조성물 Download PDF

Info

Publication number
KR101508617B1
KR101508617B1 KR20097020124A KR20097020124A KR101508617B1 KR 101508617 B1 KR101508617 B1 KR 101508617B1 KR 20097020124 A KR20097020124 A KR 20097020124A KR 20097020124 A KR20097020124 A KR 20097020124A KR 101508617 B1 KR101508617 B1 KR 101508617B1
Authority
KR
South Korea
Prior art keywords
group
poz
delete delete
target molecule
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR20097020124A
Other languages
English (en)
Korean (ko)
Other versions
KR20090114481A (ko
Inventor
제이. 밀턴 해리스
마이클 데이비드 밴틀리
윤건상
치하오 팡
프란세스코 마리아 베로네스
Original Assignee
세리나 쎄라퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 세리나 쎄라퓨틱스, 인코포레이티드 filed Critical 세리나 쎄라퓨틱스, 인코포레이티드
Publication of KR20090114481A publication Critical patent/KR20090114481A/ko
Application granted granted Critical
Publication of KR101508617B1 publication Critical patent/KR101508617B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/06—Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
    • C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/0233—Polyamines derived from (poly)oxazolines, (poly)oxazines or having pendant acyl groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00—Use of organic ingredients
    • C08K5/16—Nitrogen-containing compounds
    • C08K5/34—Heterocyclic compounds having nitrogen in the ring
    • C08K5/3412—Heterocyclic compounds having nitrogen in the ring having one nitrogen atom in the ring
    • C08K5/3415—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L79/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing nitrogen with or without oxygen or carbon only, not provided for in groups C08L61/00 - C08L77/00
    • C08L79/02—Polyamines
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L79/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing nitrogen with or without oxygen or carbon only, not provided for in groups C08L61/00 - C08L77/00
    • C08L79/04—Polycondensates having nitrogen-containing heterocyclic rings in the main chain; Polyhydrazides; Polyamide acids or similar polyimide precursors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Polyethers (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
KR20097020124A 2007-02-28 2008-02-28 활성화된 폴리옥사졸린 및 이를 포함하는 조성물 Active KR101508617B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89221207P 2007-02-28 2007-02-28
US60/892,212 2007-02-28
PCT/US2008/002626 WO2008106186A2 (en) 2007-02-28 2008-02-28 Activated polyoxazolines and compositions comprising the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR20137028233A Division KR101508621B1 (ko) 2007-02-28 2008-02-28 활성화된 폴리옥사졸린 및 이를 포함하는 조성물

Publications (2)

Publication Number Publication Date
KR20090114481A KR20090114481A (ko) 2009-11-03
KR101508617B1 true KR101508617B1 (ko) 2015-04-06

Family

ID=39721806

Family Applications (2)

Application Number Title Priority Date Filing Date
KR20097020124A Active KR101508617B1 (ko) 2007-02-28 2008-02-28 활성화된 폴리옥사졸린 및 이를 포함하는 조성물
KR20137028233A Active KR101508621B1 (ko) 2007-02-28 2008-02-28 활성화된 폴리옥사졸린 및 이를 포함하는 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR20137028233A Active KR101508621B1 (ko) 2007-02-28 2008-02-28 활성화된 폴리옥사졸린 및 이를 포함하는 조성물

Country Status (6)

Country Link
US (1) US7943141B2 (enExample)
EP (1) EP2134181A4 (enExample)
JP (1) JP5615558B2 (enExample)
KR (2) KR101508617B1 (enExample)
CN (2) CN106046370A (enExample)
WO (1) WO2008106186A2 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088884B2 (en) * 2007-09-27 2012-01-03 Serina Therapeutics, Inc. Multi-armed forms of activated polyoxazoline and methods of synthesis thereof
US8101706B2 (en) 2008-01-11 2012-01-24 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
US8110651B2 (en) 2008-01-11 2012-02-07 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
CN102159250B (zh) 2008-08-11 2014-08-06 尼克塔治疗公司 多臂的聚合烷酸酯偶联物
US20110318322A1 (en) 2009-01-12 2011-12-29 Nektar Therapeutics Conjugates of a Lysosomal Enzyme Moiety and a Water Soluble Polymer
KR20200070407A (ko) 2010-11-12 2020-06-17 넥타르 테라퓨틱스 Ｉｌ-2 부분 및 중합체의 접합체
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
US20140088021A1 (en) 2011-05-27 2014-03-27 Nektar Therapeutics Water-Soluble Polymer-Linked Binding Moiety and Drug Compounds
WO2013020005A2 (en) * 2011-08-03 2013-02-07 Anp Technologies, Inc. Oxazoline polymer compositions and use thereof
WO2013020079A2 (en) 2011-08-04 2013-02-07 Nektar Therapeutics Conjugates of an il-11 moiety and a polymer
US8383093B1 (en) 2011-11-01 2013-02-26 Serina Therapeutics, Inc. Subcutaneous delivery of poly(oxazoline) conjugates
US9416228B2 (en) * 2012-03-16 2016-08-16 Bender Analytical Holding B.V. Cross-linked polymers and medical products derived from nucleophilically activated polyoxazoline
EP3660033B9 (en) 2012-11-15 2022-06-22 Apellis Pharmaceuticals, Inc. Long-acting compstatin analogs and related compositions and methods
CN103897181B (zh) * 2012-12-27 2017-02-08 张昊 聚合物、其制备方法和应用
US9624191B2 (en) 2014-03-24 2017-04-18 International Business Machines Corporation Cyclic carbonate monomers and ring opened polycarbonates therefrom
US9215876B2 (en) 2014-03-24 2015-12-22 International Business Machines Corporation 1,3,6-dioxazocan-2-ones and antimicrobial cationic polycarbonates therefrom
GB201405391D0 (en) * 2014-03-26 2014-05-07 Applied Biomimetic As Novel polymers and process for making membranes
MA39711A (fr) 2014-04-03 2015-10-08 Nektar Therapeutics Conjugués d'une fraction d'il-15 et d'un polymère
BR112017000911B1 (pt) 2014-07-18 2023-04-11 Universiteit Gent Método para preparação de polímeros uniformes de iminoéter cíclico tendo massa molar elevada
WO2016019340A1 (en) * 2014-07-31 2016-02-04 Serina Therapeutics, Inc. Polyoxazoline antibody drug conjugates
BR112017006943B1 (pt) 2014-10-06 2020-12-01 Gatt Technologies B.V produto hemostático poroso adesivo de tecido
HK1259307A1 (zh) 2015-10-07 2019-11-29 阿佩利斯制药有限公司 给药方案
MA47290A (fr) 2015-10-08 2019-11-27 Nektar Therapeutics Combinaison d'un agoniste sélectif de l'il-2rbeta et d'un agoniste de l'il-15 à action prolongée
AU2018249627B2 (en) 2017-04-07 2025-04-03 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
IL270634B2 (en) 2017-05-15 2025-06-01 Nektar Therapeutics Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods
IL271903B2 (en) 2017-07-11 2025-04-01 Synthorx Inc Combination of unnatural nucleotides and methods therefor
SG11202000939PA (en) 2017-08-03 2020-02-27 Synthorx Inc Cytokine conjugates for the treatment of proliferative and infectious diseases
EP3502217B1 (en) * 2017-11-29 2020-05-27 Infineum International Limited Lubricating oil compositions
US10822569B2 (en) 2018-02-15 2020-11-03 Afton Chemical Corporation Grafted polymer with soot handling properties
WO2019165453A1 (en) 2018-02-26 2019-08-29 Synthorx, Inc. Il-15 conjugates and uses thereof
US10851324B2 (en) 2018-02-27 2020-12-01 Afton Chemical Corporation Grafted polymer with soot handling properties
CN110865055B (zh) * 2018-08-27 2022-10-25 香港科技大学 无金属偶联方法、偶联物及其应用
US10899989B2 (en) 2018-10-15 2021-01-26 Afton Chemical Corporation Amino acid grafted polymer with soot handling properties
EP3876973B1 (en) 2018-11-08 2025-10-22 Synthorx, Inc. Interleukin 10 conjugates and uses thereof
US11046908B2 (en) 2019-01-11 2021-06-29 Afton Chemical Corporation Oxazoline modified dispersants
EP3923974A4 (en) 2019-02-06 2023-02-08 Synthorx, Inc. IL-2 CONJUGATES AND METHODS OF USE THEREOF
US12485181B2 (en) 2019-06-28 2025-12-02 Serina Therapeutics (Al), Inc. Polyoxazoline-drug conjugates with novel pharmacokinetic properties
BR112022001554A2 (pt) * 2019-07-30 2022-03-22 Gatt Tech B V Copolímero de polioxazolina, uso do copolímero, produto médico biocompatível e processo de preparação de copolímeros
TW202124385A (zh) 2019-09-10 2021-07-01 美商欣爍克斯公司 治療自體免疫疾病之il-2接合物及使用方法
TW202203973A (zh) 2020-04-22 2022-02-01 美商默沙東藥廠 對介白素-2受體βγc二聚體具偏性且結合至非肽、水溶性聚合物之人類介白素-2結合物
EP4291242A4 (en) 2021-02-09 2025-11-26 Serina Therapeutics Al Inc POLYOXAZOLINE-LIPID CONJUGATES AND LIPID NANOPARTICLES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM
MX2024002725A (es) 2021-09-03 2024-03-15 CureVac SE Nuevas nanoparticulas lipidicas para la administracion de acidos nucleicos que comprenden fosfatidilserina.
AU2022336209B2 (en) 2021-09-03 2025-10-16 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids
US20250027108A1 (en) 2021-10-29 2025-01-23 CureVac SE Improved circular rna for expressing therapeutic proteins
US20250099614A1 (en) 2022-01-28 2025-03-27 CureVac SE Nucleic acid encoded transcription factor inhibitors
CA3248399A1 (en) 2022-01-31 2023-08-03 Genevant Sciences Gmbh POLY(ALKYLOXAZOLINE)-LIPIDS CONJUGATES AND LIPID PARTICLES CONTAINING THEM
CN114685784B (zh) * 2022-04-26 2023-09-15 北京清科胜因生物科技有限公司 一种用于核酸递送的聚(2-噁唑啉)脂质与脂质纳米颗粒及应用
CN114940756B (zh) * 2022-06-02 2023-11-07 北京清科胜因生物科技有限公司 一种聚（2-噁唑啉）脂质与脂质纳米颗粒及应用
WO2024098023A2 (en) 2022-11-04 2024-05-10 Sutro Biopharma, Inc. Interferon alpha polypeptides and conjugates
WO2024184500A1 (en) 2023-03-08 2024-09-12 CureVac SE Novel lipid nanoparticle formulations for delivery of nucleic acids
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases
WO2025158385A1 (en) 2024-01-25 2025-07-31 Genzyme Corporation Pegylated il-2 for suppressing adaptive immune response to gene therapy
EP4656669A1 (en) 2024-05-28 2025-12-03 Arkema France Fluorinated copolymers based on an oligo(2-oxazoline) macromonomer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2643403B2 (ja) * 1989-01-10 1997-08-20 花王株式会社 ポリ（ｎ―アシルアルキレンイミン）系共重合体及びその用途
US5635571A (en) * 1995-06-30 1997-06-03 Cornell Research Foundation, Inc. Polymerizable macromonomers and polymers prepared therefrom
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
AP1763A (en) * 2001-05-21 2007-08-02 Nektar Therapeutics Pulmonary administration of chemically modified insulin
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
US7056500B2 (en) * 2001-10-18 2006-06-06 Nektar Therapeutics Al, Corporation Polymer conjugates of opioid antagonists
AU2003205384A1 (en) * 2002-02-01 2003-09-02 Intradigm Corporation Polymers for delivering peptides and small molecules in vivo
CN101132812A (zh) * 2004-03-15 2008-02-27 阿拉巴马耐科塔医药公司 Hiv进入抑制剂的聚合物基组合物和结合物
US8057821B2 (en) * 2004-11-03 2011-11-15 Egen, Inc. Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making thereof
JP5081623B2 (ja) * 2005-09-01 2012-11-28 独立行政法人科学技術振興機構 オキサゾリンのランダム共重合体

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Bioconjugate Chem., 2006, Vol. 17, pp. 781-786. *
Bioconjugate Chem., 2006, Vol. 17, pp. 781-786.*
Journal of pharmaceutical Sciences, Vol. 85, No. 2, 1996년 2월, pp. 133-137 *
Journal of pharmaceutical Sciences, Vol. 85, No. 2, 1996년 2월, pp. 133-137*
Macromol. Chem. Phys. Vol. 197, 1996, pp. 2811-2826. *

Also Published As

Publication number Publication date
US20100069579A1 (en) 2010-03-18
EP2134181A4 (en) 2011-09-28
KR20090114481A (ko) 2009-11-03
KR20130125404A (ko) 2013-11-18
JP5615558B2 (ja) 2014-10-29
WO2008106186A3 (en) 2008-10-23
WO2008106186A2 (en) 2008-09-04
CN101686687A (zh) 2010-03-31
US7943141B2 (en) 2011-05-17
CN106046370A (zh) 2016-10-26
EP2134181A2 (en) 2009-12-23
JP2010529212A (ja) 2010-08-26
KR101508621B1 (ko) 2015-04-07

Similar Documents

Publication Publication Date Title
KR101508617B1 (ko) 활성화된 폴리옥사졸린 및 이를 포함하는 조성물
US9169354B2 (en) Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
US8088884B2 (en) Multi-armed forms of activated polyoxazoline and methods of synthesis thereof
JP4877225B2 (ja) ポリオキシアルキレン誘導体
US11925689B2 (en) Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
AU2012301793A1 (en) Branched discrette PEG constructs
US10864276B2 (en) Activated polyoxazolines and conjugates and compositions comprising the same
WO2022266498A1 (en) Histidine-selective polymer reagents
Lin Synthesis of Poly (ethylene glycol) Derivatives for Bioconjugation and Surface Patterning

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20090925

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20110222

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20120917

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130425

Patent event code: PE09021S01D

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20131025

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140213

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140825

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20150217

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20150330

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20150330

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20180402

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20190325

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20190325

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20200330

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20210617

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20220908

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20230329

Start annual number: 9

End annual number: 9